Buccal Cortical Separation and Lateralization for Horizontal Ridge Augmentation

November 29, 2024 updated by: Mohamed Shawky, Cairo University

Qualitative and Quantitative Assessment of Autogenous Versus Xenogenic Horizontal Ridge Augmentation After Mandibular Ridge-split with Buccal Cortical Lateralization: a Randomizedcontrolled Trial

Cases with horizontal ridge deficiency less than what is possible for ridge splitting were recruited and the buccal cortex was totally separated and lateralized at the desired distance for augmentation

Study Overview

Study Type

Interventional

Enrollment (Actual)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Cairo, Egypt
        • Faculty of Dentistry, Cairo University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

20 years to 50 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • suffering only from posterior mandibular horizontal ridge deficiency and with adequate inter-arch space to accommodate the future restoration

Exclusion Criteria:

  • Heavy smokers, diabetics, patients with bleeding problems, liver and kidney diseases, bone diseases that can affect bone healing, previous history of any ridge augmentation procedure in the posterior mandible, and those undergoing or planned for radiotherapy or chemotherapy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Lateralized buccal cortex group with xenograft
the buccal cortical bone was osteotomized and separated to be fixed in a lateralized position at the desired distance and the gap filled with Xenograft
the buccal cortex of the deficient ridge was separated and lateralized then fixed at the desired distance
Active Comparator: lateralized buccal cortex with autogenous particulate
the buccal cortex was lateralized same as in the interventional group but the gap filled with autogenous particulate
lateralized buccal cortex with autogenous particulate

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in horizontal bone gain
Time Frame: six months after the operation
the net average bone gain (in millimeters) was calculated: by calculating the difference between the immediate post operative bone width measured on the Immediate CBCT and the six months bone width measured on the six months CBCT
six months after the operation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Bone area percent
Time Frame: Six months after the operation
histomorphometric analysis of core biopsies was done at the time of implant insertion to determine the bone area percent at the implant sites
Six months after the operation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Mohammed Atef, PhD, Associate professor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 10, 2023

Primary Completion (Actual)

October 20, 2024

Study Completion (Actual)

October 20, 2024

Study Registration Dates

First Submitted

February 18, 2022

First Submitted That Met QC Criteria

March 17, 2022

First Posted (Actual)

March 18, 2022

Study Record Updates

Last Update Posted (Actual)

December 3, 2024

Last Update Submitted That Met QC Criteria

November 29, 2024

Last Verified

November 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • OMFS 3-3-9

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Horizontal Ridge Deficiency

Clinical Trials on Lateralized buccal cortex with xenograft

Subscribe